by | Jun 27, 2024 | Publications
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433516. doi: 10.1200/EDBK_433516. ABSTRACT This article endeavors to navigate the clinical journey of bispecific antibodies (BsAbs), from elucidating common toxicities and management strategies to examining novel agents and...
by | Jun 27, 2024 | Publications
Hematology. 2024 Dec;29(1):2367918. doi: 10.1080/16078454.2024.2367918. Epub 2024 Jun 27. ABSTRACT BACKGROUND: The BCL2 interacting protein 3-like (BNIP3L) protein is involved in multiple myeloma (MM) development and progression. This study aims to explore the...
by | Jun 27, 2024 | Publications
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):927-932. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.042. ABSTRACT OBJECTIVE: To investigate the correlation between the stimulator of interferon genes (STING ) promoter polymorphism and the susceptibility to...
by | Jun 27, 2024 | Publications
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):952-956. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.046. ABSTRACT Multiple myeloma (MM) is an incurable malignant plasma cell diseases, the incidence of which is increasing year by year. The application of...
by | Jun 27, 2024 | Publications
Biomolecules. 2024 Jun 19;14(6):725. doi: 10.3390/biom14060725. ABSTRACT Immunomodulatory imide drugs (IMiDs) play a crucial role in the treatment landscape across various stages of multiple myeloma. Despite their evident efficacy, some patients may exhibit primary...
by | Jun 27, 2024 | Publications
Biomedicines. 2024 May 23;12(6):1153. doi: 10.3390/biomedicines12061153. ABSTRACT INTRODUCTION: After receiving different lines of treatment, multiple myeloma patients tend to present with less secretory and more frequent extramedullary disease. These features make...
